Scinai Immunotherapeutics (SCNI) Stock Statistics & Valuation Metrics

Scinai Immunotherapeutics has a market cap or net worth of $2.05M. The enterprise value is $1.38M.

Scinai Immunotherapeutics has 3,535,489 shares outstanding. The number of shares has decreased by -2.65% in one year.

Scinai Immunotherapeutics’s return on equity (ROE) is -1.03 and return on invested capital (ROIC) is -72.73%.

The current PE Ratio of Scinai Immunotherapeutics is ―. Scinai Immunotherapeutics’s PEG ratio is 0.00.

In the last 12 months, Scinai Immunotherapeutics had revenue of 1.31M and earned -8.31M in profits. Earnings per share was -3.60.

In the last 12 months, operating cash flow was -5.69M and capital expenditures -16.02K, giving a free cash flow of -5.71M billion.

Scinai Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Scinai Immunotherapeutics upcoming earnings date is May 7, 2026, TBA (Confirmed).

Scinai Immunotherapeutics as a current ratio of 1.30, with Debt / Equity ratio of 27.98%

In the past 12 months, Scinai Immunotherapeutics has paid 0.00 in taxes.

Scinai Immunotherapeutics EV to EBITDA ratio is -0.35, with an EV/FCF ratio of -0.37.

Scinai Immunotherapeutics has $989.00K in cash and marketable securities with $2.36M in debt, giving a net cash position of -$1.37M billion.

Gross margin is -202.29%, with operating margin of -575.29%, and net profit margin of -633.64%.

The average price target for Scinai Immunotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―